ATXS
Price
$12.98
Change
+$0.08 (+0.62%)
Updated
Dec 24 closing price
Capitalization
740.96M
69 days until earnings call
Intraday BUY SELL Signals
ORKA
Price
$32.12
Change
+$0.41 (+1.29%)
Updated
Dec 24 closing price
Capitalization
1.55B
Intraday BUY SELL Signals
Interact to see
Advertisement

ATXS vs ORKA

Header iconATXS vs ORKA Comparison
Open Charts ATXS vs ORKABanner chart's image
Astria Therapeutics
Price$12.98
Change+$0.08 (+0.62%)
Volume$212.7K
Capitalization740.96M
Oruka Therapeutics
Price$32.12
Change+$0.41 (+1.29%)
Volume$261.98K
Capitalization1.55B
ATXS vs ORKA Comparison Chart in %
ATXS
Daily Signal:
Gain/Loss:
ORKA
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
ATXS vs. ORKA commentary
Dec 26, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and ORKA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 26, 2025
Stock price -- (ATXS: $12.98 vs. ORKA: $32.12)
Brand notoriety: ATXS and ORKA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 16% vs. ORKA: 51%
Market capitalization -- ATXS: $740.96M vs. ORKA: $1.55B
ATXS [@Biotechnology] is valued at $740.96M. ORKA’s [@Biotechnology] market capitalization is $1.55B. The market cap for tickers in the [@Biotechnology] industry ranges from $117.47B to $0. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileORKA’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • ORKA’s FA Score: 1 green, 4 red.
According to our system of comparison, ORKA is a better buy in the long-term than ATXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 4 TA indicator(s) are bullish while ORKA’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 4 bullish, 3 bearish.
  • ORKA’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, ORKA is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а +2.69% price change this week, while ORKA (@Biotechnology) price change was +13.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.88%. For the same industry, the average monthly price growth was +4.46%, and the average quarterly price growth was +55.39%.

Reported Earning Dates

ATXS is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+2.88% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORKA($1.56B) has a higher market cap than ATXS($741M). ORKA YTD gains are higher at: 65.652 vs. ATXS (45.190). ORKA has more cash in the bank: 349M vs. ATXS (228M). ORKA has less debt than ATXS: ORKA (1.91M) vs ATXS (4.46M).
ATXSORKAATXS / ORKA
Capitalization741M1.56B48%
EBITDA-136.51MN/A-
Gain YTD45.19065.65269%
P/E RatioN/AN/A-
Revenue706KN/A-
Total Cash228M349M65%
Total Debt4.46M1.91M233%
FUNDAMENTALS RATINGS
ATXS vs ORKA: Fundamental Ratings
ATXS
ORKA
OUTLOOK RATING
1..100
8989
VALUATION
overvalued / fair valued / undervalued
1..100
78
Overvalued
5
Undervalued
PROFIT vs RISK RATING
1..100
86100
SMR RATING
1..100
98100
PRICE GROWTH RATING
1..100
3635
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5085

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORKA's Valuation (5) in the null industry is significantly better than the same rating for ATXS (78) in the Biotechnology industry. This means that ORKA’s stock grew significantly faster than ATXS’s over the last 12 months.

ATXS's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as ORKA (100) in the null industry. This means that ATXS’s stock grew similarly to ORKA’s over the last 12 months.

ATXS's SMR Rating (98) in the Biotechnology industry is in the same range as ORKA (100) in the null industry. This means that ATXS’s stock grew similarly to ORKA’s over the last 12 months.

ORKA's Price Growth Rating (35) in the null industry is in the same range as ATXS (36) in the Biotechnology industry. This means that ORKA’s stock grew similarly to ATXS’s over the last 12 months.

ORKA's P/E Growth Rating (100) in the null industry is in the same range as ATXS (100) in the Biotechnology industry. This means that ORKA’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSORKA
RSI
ODDS (%)
Bearish Trend 3 days ago
58%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
77%
Bearish Trend 3 days ago
70%
Momentum
ODDS (%)
Bullish Trend 3 days ago
77%
Bullish Trend 3 days ago
67%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
71%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
67%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bullish Trend 3 days ago
69%
Advances
ODDS (%)
Bullish Trend 5 days ago
80%
Bullish Trend 5 days ago
75%
Declines
ODDS (%)
Bearish Trend 10 days ago
89%
Bearish Trend 9 days ago
77%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
72%
Bearish Trend 3 days ago
79%
Aroon
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signal:
Gain/Loss:
ORKA
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ALBCX91.530.34
+0.37%
Alger Growth & Income C
HAITX55.990.16
+0.29%
Hartford Core Equity R6
FLRAX43.960.12
+0.27%
Nuveen Large Cap Select A
PASPX10.180.01
+0.10%
PACE Alternative Strategies P
DHLSX32.22N/A
N/A
Diamond Hill Long-Short I

ORKA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORKA has been loosely correlated with SYRE. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ORKA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORKA
1D Price
Change %
ORKA100%
+1.29%
SYRE - ORKA
56%
Loosely correlated
-0.54%
ELVN - ORKA
47%
Loosely correlated
+1.21%
VRDN - ORKA
46%
Loosely correlated
+0.53%
ATXS - ORKA
46%
Loosely correlated
+0.62%
APGE - ORKA
46%
Loosely correlated
+1.02%
More